Piflufolastat F 18 for PSMA PET imaging in prostate cancer

VernacularTitle:用于前列腺癌患者PSMA PET显像的Piflufolastat F 18
Author: Jing-Tian SHI ¹ ; Ting YANG ; Chao-Yang CHEN ; Ran WEI ; Xuan-Ling ZHANG ; Xiao-Juan HU ; Ying ZHOU
Author Information

1. 北京大学第一医院药剂科,北京 100034;北京大学第一医院宁夏妇女儿童医院/宁夏回族自治区妇幼保健院药剂科,宁夏回族自治区银川 750001
Keywords: Piflufolastat F 18; prostate cancer; prostate specific membrane antigen; positron emission computed tomography
From: The Chinese Journal of Clinical Pharmacology 2024;40(12):1835-1838
CountryChina
Language:Chinese
Abstract: On May 27,2021,the U.S.Food and Drug Administration(FDA)officially approved Lantheus'PYLARIFY?(Piflufolastat F 18,18 F-labeled imaging agent),which can be used for positron emission computed tomography(PET)of prostate-specific membrane antigen(PSMA)-positive lesions in prostate cancer patients to accurately identify prostate cancer with suspected metastasis or recurrence.Piflufolastat F 18 is approved by FDA for two indications.The first is the initial staging for suspected metastatic lesions in men with newly diagnosed prostate cancer.The second is restaging,with the goal of identifying lesions in the setting of biochem ical recurrence.